The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial

安慰剂 氟西汀 双盲 随机对照试验 临床试验 医学 心理学 萧条(经济学) 物理疗法 认知行为疗法 精神科 临床心理学 内科学 认知 替代医学 宏观经济学 病理 经济 受体 血清素
作者
Christopher G. Davey,Andrew M. Chanen,Sarah Hetrick,Sue Cotton,Aswin Ratheesh,G. Paul Amminger,John Koutsogiannis,Mark Phelan,Edward J. Mullen,Ben J. Harrison,Simon Rice,Alexandra Parker,Olivia Dean,Amber Weller,Melissa Kerr,Amelia L. Quinn,Lisa Catania,Nikolaos Kazantzis,Patrick D. McGorry,Michael Berk
出处
期刊:The Lancet Psychiatry [Elsevier BV]
卷期号:6 (9): 735-744 被引量:99
标识
DOI:10.1016/s2215-0366(19)30215-9
摘要

Summary

Background

Medication is commonly used to treat youth depression, but whether medication should be added to cognitive behavioural therapy (CBT) as first-line treatment is unclear. We aimed to examine whether combined treatment with CBT and fluoxetine was more effective than CBT and placebo in youth with moderate-to-severe major depressive disorder.

Methods

The Youth Depression Alleviation–Combined Treatment (YoDA-C) trial was a randomised, double-blind, placebo-controlled, multicentre clinical trial. Participants were aged 15–25 years with moderate-to-severe MDD and had sought care at one of four clinical centres in metropolitan Melbourne, Australia. Patients were randomly assigned (1:1) to receive CBT for 12 weeks, plus either fluoxetine or placebo. Participants began on one 20 mg capsule of fluoxetine or one placebo pill per day. All participants received CBT, delivered by therapists in weekly 50-minute sessions and attended interviews at baseline, and at weeks 4, 8, and 12, during which they completed assessments with research assistants. Participants saw a psychiatrist or psychiatry trainee to complete medical assessments at the same timepoints. The primary outcome was change in the interviewer-rated Montgomery-Åsberg Depression Rating Scale (MADRS) score at 12 weeks. The trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12612001281886).

Findings

153 participants (mean age 19·6 years [SD 2·7]) were enrolled from Feb 20, 2013, to Dec 13, 2016. 77 (50%) patients were allocated to CBT and placebo and 76 (50%) to CBT and fluoxetine. Participants had severe depression at baseline (mean MADRS score 33·6 [SD 5·1] in the CBT and placebo group and 32·2 [5·6] in the CBT and fluoxetine group), with high proportions of participants with anxiety disorder comorbidity (47 [61%] in the CBT and placebo group and 49 [64%] in the CBT and fluoxetine group) and past-month suicidal ideation (55 [71%] in the CBT and placebo group and 59 [78%] in the CBT and fluoxetine group). 59 (77%) participants in the CBT and placebo group and 64 (84%) in the CBT and fluoxetine group completed follow-up at week 12. After 12 weeks of treatment both groups showed a reduction in MADRS scores (−13·7, 95% CI −16·0 to −11·4, in the CBT and placebo group and −15·1, −17·4 to −12·9, in the CBT and fluoxetine group). There was no significant between-group difference in MADRS scores (−1·4, −4·7 to 1·8; p=0·39). There were five suicide attempts in the CBT and placebo group and one suicide attempt in the CBT and fluoxetine group (odds ratio 0·2, 0·0–1·8; p=0·21), and no significant between-group differences for other suicidal behaviours.

Interpretation

We did not find evidence that the addition of fluoxetine (rather than placebo) to CBT further reduced depressive symptoms in young people with moderate-to-severe MDD. Exploratory analyses showed that the addition of medication might be helpful for patients with comorbid anxiety symptoms and for older youth.

Funding

Australian National Health and Medical Research Council.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
科研通AI6.4的应助被zxy采纳,获得10
1秒前
乐乐的应助被Vater采纳,获得10
1秒前
LIUDAN发布了新的文献求助10
1秒前
852的应助被皮皮采纳,获得10
2秒前
科研通AI6.2的应助被Daria采纳,获得30
2秒前
可爱的函函的应助被开心德地采纳,获得10
2秒前
2秒前
2秒前
冬冬不是发布了新的文献求助30
3秒前
3秒前
Ava的应助被UCASGuo采纳,获得10
3秒前
烟花的应助被默默采纳,获得10
3秒前
3秒前
何莉完成签到,获得积分10
3秒前
科研通AI2S的应助被酷酷的仇天采纳,获得10
4秒前
4秒前
朴实傲晴完成签到,获得积分10
4秒前
周思完成签到,获得积分10
4秒前
Rr完成签到,获得积分10
5秒前
molihuakai的应助被开心德地采纳,获得10
5秒前
罗二狗发布了新的文献求助10
5秒前
Twinkle发布了新的文献求助30
5秒前
罗二狗发布了新的文献求助10
5秒前
Ibuprofen完成签到,获得积分10
7秒前
7秒前
7秒前
汌舟发布了新的文献求助10
8秒前
打打的应助被开心德地采纳,获得10
8秒前
313发布了新的文献求助10
8秒前
Liu Luke完成签到,获得积分10
8秒前
11秒前
科研通AI6.4的应助被LIUDAN采纳,获得10
11秒前
香蕉觅云的应助被开心德地采纳,获得10
11秒前
11秒前
细腻芹菜完成签到,获得积分10
11秒前
11秒前
12秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189382
求助须知:如何正确求助?哪些是违规求助? 9576691
关于积分的说明 21849410
捐赠科研通 7787318
什么是DOI,文献DOI怎么找? 3435538
关于科研通互助平台的介绍 2559748
邀请新用户注册赠送积分活动 2482509